drugset / Trial / NCT01335256

Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies

NCT01335256

Phase 1 Completed 10 enrolled Bayer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Clinical study to determine safety, tolerability, and maximum tolerated dose of BAY1000394 given in 4 week on / 2 week off schedule to patients with advanced solid tumors

Timeline

Start
2010-12
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Roniciclib Small molecule Oral

Indications